Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
APY29 occupies IRE1α's kinase ATP-binding site to activate RNase-mediated XBP1 mRNA splicing even without upstream endoplasmic reticulum stress
In a recent publication in Cell Stem Cell
2009 Oct-Dec
5) in any of the groups
de Darko E
Rofecoxib Size:Solid 2 mg APY29 occupies IRE1α's kinase ATP-bindingRofecoxib is a nonsteroidal anti inflammatory drug (NSAID) that has now been withdrawn over safety concerns. Rofecoxib exhibits anti inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of rofecoxib is believed to be due to inhibition of prostaglandin synthesis, via inhibition of cyclooxygenase 2 (COX 2). At therapeutic concentrations in humans, rofecoxib does not inhibit the cyclooxygenase 1 (COX 1) isoenzyme.
US$ 1584.84
US$ 2038.96
US$ 2038.96
US$ 1828.05
US$ 2075.34
US$ 350.00
US$ 1508.21
US$ 2529.47
US$ 2576.42
US$ 500.00
US$ 1000.00